Results 41 to 50 of about 38,526 (184)

Biomimetic Cell Membrane‐Coated MOFs System for Targeted Cancer Therapy

Advanced Science, EarlyView.
Biomimetic MOF‐based drug delivery nanoplatforms synthesized using liposomes or cell membranes as camouflage for multiple cancer therapeutics. ABSTRACT The integration of metal‐organic frameworks (MOFs) with cell membrane coatings has emerged as a revolutionary strategy to enhance the therapeutic efficacy of cancer nanomedicine.
Qilu Wu, Jia Song Deon Chon, Yuxiao Feng, Kang Liang, Shiming Li, Can Yang Zhang, Jun Ge   +6 more
wiley   +1 more source

Chalazia development in multiple myeloma: a new complication associated with bortezomib therapy

Hematology Reports, 2015
Multiple myeloma (MM) is a neoplasm of plasma cells within the bone marrow. A major impact on improving survival in MM has been the use of the boronic acid-derived proteasome inhibitor bortezomib, a first-in-class selective inhibitor of the 26S ...
Charles Yun, Nikhil Mukhi, Valerie Kremer, Roman Shinder, Vaibhav Verma, Olcay Batuman   +5 more
doaj   +1 more source

CircRSU1 Activates the hnRNPA1/HIF‐1α/CD24 Signaling Axis, Promoting Stemness Features of Hepatocellular Carcinoma

Advanced Science, EarlyView.
This study reveals circRSU1 with important oncogenic roles in hepatocellular carcinoma (HCC). CircRSU1, highly abundant in HCC, interacts with and stabilizes hnRNPA1 from ubiquitination and degradation. This stabilization facilitates hnRNPA1 binding to the internal ribosome entry site of HIF1A to increase HIF‐1α protein translation.
Shuting Xue, Danduo Wei, Yongzhi Zhao, Jinchang Pan, Hanyuan Zhang, Niya Liu, Jianjuan Zhang, Jiaxin Liu, Jianping Jin, Mu Xiao, Xinhua Feng, Aifu Lin, Lei Zhao, Stephanie Roessler, Junfang Ji   +14 more
wiley   +1 more source

Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib

Redox Biology, 2020
Proteasome inhibitors have great success for their therapeutic potential against hematologic malignancies. First generation proteasome inhibitor bortezomib induced peripheral neuropathy is considered as a limiting factor in chemotherapy and its second ...
Ayse Tarbin Jannuzzi, Sema Arslan, Ayse Mine Yilmaz, Gulce Sari, Hande Beklen, Lucía Méndez, Maria Fedorova, Kazim Yalcin Arga, Betul Karademir Yilmaz, Buket Alpertunga   +9 more
doaj   +1 more source

PIK3CA Mutations Downregulate PPT1 to Promote Adipogenesis by Suppressing P300 Depalmitoylation and Phase Separation

Advanced Science, EarlyView.
This study demonstrates that somatic PIK3CA mutations suppress PPT1 expression via activation of the PI3K–AKT–c‐JUN axis. This reduction in PPT1 weakens its interaction with P300, thereby increasing palmitoylation at C1176 of P300 and protecting P300 from lysosomal degradation.
Hongrui Chen, Zening Huang, Rui Chang, Wei Gao, Yajing Qiu, Bin Sun, Chen Hua, Xiaoxi Lin   +7 more
wiley   +1 more source

Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers

Scientific Reports
Repurposing of FDA-approved drugs is a quick and cost-effective alternative to de novo drug development. Here, we identify genes involved in bortezomib sensitivity, predict cancer types that may benefit from treatment with bortezomib, and evaluate the ...
Peter Larsson, Maxim Olsson, Sithumini Sarathchandra, Anna Fäldt Beding, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z. Parris   +8 more
doaj   +1 more source

N6-methyladenosine-modified circ_0000337 sustains bortezomib resistance in multiple myeloma by regulating DNA repair

Frontiers in Cell and Developmental Biology
Studies have shown that bortezomib resistance in multiple myeloma (MM) is mediated by the abnormalities of various molecules and microenvironments. Exploring these resistance mechanisms will improve the therapeutic efficacy of bortezomib.
Siyi Jiang, Lili Gao, Jian Li, Fangrong Zhang, Yanan Zhang, Jing Liu   +5 more
doaj   +1 more source

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

Haematologica, 2012
The phase III MMY-3021 study compared safety and efficacy of subcutaneous versus intravenous administration of the proteasome inhibitor bortezomib in patients with relapsed myeloma.
Bertrand Arnulf, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Helgi van de Velde, Huaibao Feng, Andrew Cakana, William Deraedt, Philippe Moreau   +9 more
doaj   +1 more source

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib

Parasites & Vectors, 2009
The proteasome inhibitor and anti-cancer drug bortezomib was tested for in vitro activity against bloodstream forms of Trypanosoma brucei. The concentrations of bortezomib required to reduce the growth rate by 50% and to kill all trypanosomes were 3.3 nM
Wang Xia, Steverding Dietmar
doaj   +1 more source

Proteasome inhibitor bortezomib ameliorates intestinal injury in mice. [PDF]

PLoS ONE, 2012
BACKGROUND: Bortezomib is a proteasome inhibitor that has shown impressive efficacy in the treatment of multiple myeloma. In mice, the addition of dextran sulfate sodium (DSS) to drinking water leads to acute colitis that can serve as an experimental ...
Koichi Yanaba, Yoshihide Asano, Yayoi Tada, Makoto Sugaya, Takafumi Kadono, Shinichi Sato   +5 more
doaj   +1 more source